Daewoong Market Cap ($447.54 Million)
Market Cap & Net Worth: Daewoong (003090)
Daewoong market cap. Daewoong (KO:003090) has a market capitalization of $447.54 Million (₩660.40 Billion) as of November 3, 2026. Listed on the KO stock exchange, this Korea-based company holds position #12518 globally and #352 in its home market, demonstrating a 5.08% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Daewoong's stock price ₩15710.00 by its total outstanding shares 42036875 (42.04 Million). Also see Daewoong cash conversion from operations for how efficiently the company converts equity into cash flow.
Daewoong Market Cap History (2015–2026)
Daewoong market cap history from 2015 to 2026. Data shows growth from $309.56 Million to $447.54 Million (2.71% CAGR). Check 003090 stock price and chart for real-time trading data and today's change.
Daewoong Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Daewoong's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Daewoong equity growth rate to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.00x
Daewoong's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.00x
Daewoong's market cap is 0.00 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $243.67 Million | $1.02 Trillion | $19.83 Billion | 0.00x | 0.01x |
| 2017 | $538.23 Million | $1.12 Trillion | $66.25 Billion | 0.00x | 0.01x |
| 2018 | $498.06 Million | $1.23 Trillion | $29.86 Billion | 0.00x | 0.02x |
| 2019 | $365.22 Million | $1.37 Trillion | $62.44 Billion | 0.00x | 0.01x |
| 2020 | $1.42 Billion | $1.36 Trillion | $98.38 Billion | 0.00x | 0.01x |
| 2021 | $880.31 Million | $1.51 Trillion | $78.81 Billion | 0.00x | 0.01x |
| 2022 | $579.73 Million | $1.70 Trillion | $102.57 Billion | 0.00x | 0.01x |
| 2023 | $588.27 Million | $1.81 Trillion | $152.67 Billion | 0.00x | 0.00x |
| 2024 | $615.34 Million | $1.94 Trillion | $57.89 Billion | 0.00x | 0.01x |
| 2025 | $628.16 Million | $2.07 Trillion | $175.06 Billion | 0.00x | 0.00x |
Competitor Companies of 003090 by Market Capitalization
Companies near Daewoong in the global market cap rankings as of November 3, 2026. Also see Daewoong total assets for a full breakdown of the balance sheet.
Key companies related to Daewoong by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #516 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #536 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #591 globally with a market cap of $45.45 Billion USD ( CN¥310.59 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #618 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #516 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #536 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.55 |
| #591 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.45 Billion | CN¥48.69 |
| #618 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of Daewoong (2015–2026)
Market capitalization of Daewoong from 2015 to today. Between 2015 and today, Daewoong's market cap moved from $309.56 Million to $ 447.54 Million, with a yearly change of 2.71%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩447.54 Million | -28.75% |
| 2025 | ₩628.16 Million | +2.08% |
| 2024 | ₩615.34 Million | +4.60% |
| 2023 | ₩588.27 Million | +1.47% |
| 2022 | ₩579.73 Million | -34.15% |
| 2021 | ₩880.31 Million | -38.08% |
| 2020 | ₩1.42 Billion | +289.24% |
| 2019 | ₩365.22 Million | -26.67% |
| 2018 | ₩498.06 Million | -7.46% |
| 2017 | ₩538.23 Million | +120.88% |
| 2016 | ₩243.67 Million | -21.28% |
| 2015 | ₩309.56 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of Daewoong was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $447.54 Million USD |
| MoneyControl | $447.54 Million USD |
| MarketWatch | $447.54 Million USD |
| marketcap.company | $447.54 Million USD |
| Reuters | $447.54 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Daewoong
Daewoong Co., Ltd., together with its subsidiaries, engages in the manufacture and sale of pharmaceuticals in South Korea. It is also involved in the real estate rental business; provision of lifestyle-related disease prevention research, business management, public affairs, and facility management services; and processing and sale of food products. The company was formerly known as Daewoong Phar… Read more